A team of investigators sought to understand COVID-19 characteristics in people with multiple sclerosis and identify high-risk patients.
The American Academy of Neurology Institute released a 2020 quality measurement set to improve care outcomes for patients with multiple sclerosis.
Study researchers evaluated the diagnostic and prognostic value of myeloid microvesicles as multiple sclerosis biomarkers in the clinical setting.
Study investigators evaluated the value of integrating structural and functional network MRI measures to predict clinical disability deterioration of multiple sclerosis.
Study researchers assessed the long-term disability risk following pregnancy in women with multiple sclerosis.
A team of researchers surveyed patients with multiple sclerosis to determine if influenza vaccine uptake would not meet public health targets.
In this editorial, study researchers discussed the possible prodromal phase of multiple sclerosis and its role in the early diagnosis of the disease.
This editorial report explored a population-based cohort study on depression and anxiety in pregnant patients with MS.
Study researchers assessed the morphometric and microstructural gray matter differences between primary progressive and relapsing remitting multiple sclerosis.
Study investigators used the visual pathway to assess the promyelinating and neuroprotective effects of alemtuzumab in multiple sclerosis.
Study researchers examined the different paradigms on the pathophysiology of MS, the outside-in and the inside-out theories.
A team of investigators sought to determine whether κ- and λ-FLC index may predict early multiple sclerosis disease activity independent of demographics, clinical, and MRI characteristics.
Researchers called for effective tools for earlier identification of secondary progressive MS to improve long-term outcomes in patients with the disease.
This case study examines 2 patients with relapsing remitting multiple sclerosis, under dimethyl fumarate treatment, who developed severe herpes zoster infection.
Researchers advocate for implementing steroid therapy on an individual basis, not as routine.
Among patients with multiple sclerosis, those of older age and higher comorbidity burden are associated with the highest care consumption.
Study researchers sought to assess the effects of pregnancy on relapse pattern in patients with neuromyelitis optica spectrum disorder.
Investigators strove to quantify imaging patterns of central nervous system damage in MOGAD during the remission stage, and to compare it with NMOSD-AQP4 and MS.
The labeling for Aubagio has been updated to include safety data from the pediatric clinical trial program.
The STOP-Bang Questionnaire may be an effective tool in screening patients with multiple sclerosis for moderate to severe obstructive sleep apnea.
Investigators analyzed the frequency and severity of relapses in patients with relapsing-remitting multiple sclerosis who were treated with cladribine tablets.
Altered microRNAs (miRNAs) detected in sera may be used as markers of gray matter lesion demyelination in patients with multiple sclerosis.
Study researchers investigated a marker of endogenous serum N-acetylglucosamine levels in patients with multiple sclerosis.
Improvements in the treatment and management of pediatric-onset multiple sclerosis (MS) have resulted in reductions in persistent disability in patients with MS.
In order to assess asymptomatic infections and immunologic responses to COVID-19, a team of researchers tested for SARS-CoV-2 antibodies in a multiple sclerosis cohort.
Investigators examined the relationships between morphological and diffusional properties in cerebral gray matter and physical and cognitive performance in patients with relapsing-remitting MS.
Researchers aimed to define new subtypes of MS based on objective assessments of the pathological changes seen on MRI scans, rather than on the observed changes in the clinical symptoms.
Currently, the FDA-approved route of administration of Tysabri for MS is through intravenous infusion.
Investigators conducted a survey to assess the incidence of COVID-19 in patients with multiple sclerosis as well as the influence of their comorbidities and treatments on outcomes.
The cognitive effects of multiple sclerosis are often associated with later stages of the disease. However, there may be some indicators of its involvement in patients with early stages. Understanding these factors — some of which are psychological and some of which are clinical — could help with treating and monitoring patients.